PCa Commentary #169 – ANDROGEN DEPRIVATION THERAPY (ADT) and Radiotherapy: Basic Mechanisms and New Developments.

by Dr. Ed Weber | Sep 21, 2022 | PCa Commentary

Any man diagnosed with prostate cancer is likely aware that lowering testosterone (T) levels achieves control of the cancer at various stages of the disease. Question: What is the underlying biology and function of that therapeutic maneuver (androgen deprivation...

PCa Commentary #168 – De Novo Metastatic Castration-Sensitive Prostate Cancer: (mHSPC) — Many Options for Treatment

by Dr. Ed Weber | Aug 24, 2022 | PCa Commentary

The incidence of metastatic prostate cancer at diagnosis, i.e., metastatic hormone-sensitive prostate cancer has increased, partly due to the fallout from the 2012 Task Force recommendation against screening, particularly increasing in men older than 75 years. This...

PCa Commentary #167 – PROVENGE – AN UPDATE: What Has Been Learned Since FDA  Approval in 2010?

by Dr. Ed Weber | Jul 20, 2022 | PCa Commentary

Provenge (Dendreon, Inc, ‘Sipuleucel-T’) is an autologous (i.e., based on a patient’s own cells) vaccine targeted to the highly expressed prostatic acid phosphatase (PAP) antigen on malignant prostate cells. It was FDA approved based on the IMPACT trial reporting a...

PCa Commentary #166 – CAR-T Cell IMMUNOTHERAPY OF PROSTATE CANCER: Promising, but Currently Only a “Work-in-Progress.”

by Dr. Ed Weber | Jun 1, 2022 | PCa Commentary

Years before there was even a glimmer of technical possibility for effective immunotherapy, there was great hope for harassing the immune system to combat cancer.  The earliest realization of this hope came with the FDA approval of Provenge in April 2010 and...

PCa Commentary #165 – Lutetium-177—PSMA-617 Therapy: Now FDA approved and to be available shortly: The Treatment in Context

by Dr. Ed Weber | May 17, 2022 | PCa Commentary

[Prostate Cancer Commentary Vol. 143 PCa Commentary #143: ANTI-PSMA 177-LUTETIUM RADIOLIGAND THERAPY discusses the mechanism of action of 177Lu therapy, its background and outcome of early studies] (control+click above link to follow or visit...

PCa Commentary #164 – Recurrent Prostate Cancer – An Emerging Management Trifecta:    PSMA PET/CT; Oligometastatic Cancer; Focal CyberKnife Treatment. 

by Dr. Ed Weber | Apr 19, 2022 | PCa Commentary

When the PSA is elevated following initial potentially curative treatment with prostatectomy or radiation therapy, the customary management response has been hormone suppression with Lupron, Degarilix or Relugolix. This Commentary highlights an alternative...